Sander J. van Deventer
Chief Executive Officer chez VectorY BV
Profil
Sander J.
van Deventer was the founder of Amsterdam Molecular Therapeutics (AMT) Holding NV, founded in 1998, where he served as Director from 2010 to 2013.
He was also the founder of uniQure NV, founded in 1998, where he held the title of Executive VP-Research & Product Development from 2019 to 2020.
Additionally, Dr. van Deventer founded NewAmsterdam Pharma BV in 2012 and served as Chief Executive Officer from 2012 to 2013.
Dr. van Deventer is also the founder of VectorY BV.
Dr. van Deventer's current job(s) include being a Director at Staten Biotechnology BV, a Director at Covicept Therapeutics, Inc., an Operating Partner at Forbion Capital Partners Management Holding BV since 2007, a Professor at Leids Universitair Medisch Centrum since 2008, and a Member-Supervisory Board at Hookipa Biotech AG since 2013.
Dr. van Deventer's former job(s) include being Vice Chairman at Borean Pharma ApS, Director at enGene, Inc., Independent Director at Argos Therapeutics, Inc. from 2011 to 2018, Director at RSPR Pharma AB, Director at gIcare Pharma, Inc., Independent Non-Executive Director at HOOKIPA Pharma, Inc. from 2011 to 2020, Professor-Experimental Medicine at Academic Medical Center from 1995 to 2012, and Professor-Experimental Medicine at the University of Amsterdam from 2002 to 2008.
Dr. van Deventer's education history includes undergraduate and doctorate degrees from the University of Amsterdam.
Postes actifs de Sander J. van Deventer
| Sociétés | Poste | Début |
|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 08/01/2007 |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Director/Board Member | - |
Leids Universitair Medisch Centrum
 Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | 01/01/2008 |
Staten Biotechnology BV
 Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Director/Board Member | - |
Covicept Therapeutics, Inc.
 Covicept Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Covicept Therapeutics, Inc. is a newly founded company based in California, USA. Covicept Therapeutics is focused on developing drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. The American company is backed by $2.30 million in seed funding and operational support from leading European VC firm Forbion. Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection, and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans, allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and antiviral medications. The company was founded by Sam Tsimikas, Philip Gordts, and Jeffrey Esko. Sam Tsimikas has been the CEO since incorporation. | Director/Board Member | - |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Chief Executive Officer | 07/11/2022 |
Anciens postes connus de Sander J. van Deventer
| Sociétés | Poste | Fin |
|---|---|---|
| UNIQURE N.V. | Founder | 14/09/2020 |
| HOOKIPA PHARMA INC. | Director/Board Member | 19/06/2020 |
| ARGOS THERAPEUTICS, INC. | Director/Board Member | 01/01/2018 |
| ░░░░░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Sander J. van Deventer
| University of Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| UNIQURE N.V. | Health Technology |
| HOOKIPA PHARMA INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Borean Pharma ApS provides biopharmaceuticals drugs and protein engineering services. Its two main components of technology platform are CTLD library technology and trimerisation technology. The company was founded by Hans Christian Thøgersen and Michael Etzerodt in 1997 and is located in Aarhus, Denmark. | Health Technology |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Leids Universitair Medisch Centrum
Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands. | Health Services |
RSPR Pharma AB
 RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
gIcare Pharma, Inc.
 gIcare Pharma, Inc. Pharmaceuticals: MajorHealth Technology gIcare Pharma, Inc. develops gastrointestinal drugs. It develops orally-administered drug GIC-1001 which provides colonic analgesia. The company was founded by Patrick Colin and Maxime Ranger in 2011 and is headquartered in Montreal, Canada. | Health Technology |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Covicept Therapeutics, Inc.
Covicept Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Covicept Therapeutics, Inc. is a newly founded company based in California, USA. Covicept Therapeutics is focused on developing drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. The American company is backed by $2.30 million in seed funding and operational support from leading European VC firm Forbion. Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection, and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans, allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and antiviral medications. The company was founded by Sam Tsimikas, Philip Gordts, and Jeffrey Esko. Sam Tsimikas has been the CEO since incorporation. | Commercial Services |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Commercial Services |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
